PFA 100 Evaluation and Reference Interval HOACNY

Inclusion criteria

• Age 18 years or older
• Able to consent to study

Exclusion criteria

from entire study

• Primary hemostasis diagnosis

• Von Willebrand Disease
• Bernard-Soulier syndrome
• Glanzmann thrombasthenia
• Idiopathic thrombocytopenic purpura
• Drug-induced thrombocytopenia
• Heparin-induced thrombocytopenia
• Thrombotic thrombocytopenic purpura
• Hemolytic uremic syndrome
• Participant is on anticoagulant therapy

• Specifically thienopyrdines [Ticlopidine, Clopidogrel] and GPIIb/IIIa inhibitors [ReoPro, Aggrastat, Integrilin]
• Participant is on medication that contains ASA or aspirin (see list below in Study Procedure)
• Participant is on nonsteroidal anti-inflammatory agents that are known to induce temporary platelet dysfunction (see list below in Study Procedure)
• Participant is on non-prescription medications containing aspirin (see list below in Study Procedure)
• PFA-100 result falls outside of reference interval listed in the package insert (suggested criteria in the PFA-100 Evaluation Protocol as described in the PFA-100 System: Getting Started Guide)
• If hematocrit is less than 35%
• If platelets are less than 150 x10^3/uL

Exclusion criteria

from Cohort B but not Cohort A

• Potential for adverse reactions between current medication and aspirin as dictated by staff pharmacist
• Allergy to ASA or aspirin
• Previous allergic reaction to ASA or aspirin
• Participant is pregnant
• Asthma, or history of, with nasal polyps and rhinitis
• Stomach ulcers or bleeding
• Severe kidney disease
• Severe liver disease
• Hemophilia
• Pregnant or breast feeding